Effect of Sildenafil Citrate on Endometrial Thickness and Pregnancy Rate in Frozen-Thawed Embryo Transfer Cycles

Research Article

Austin J Obstet Gynecol. 2020; 7(1): 1150.

Effect of Sildenafil Citrate on Endometrial Thickness and Pregnancy Rate in Frozen-Thawed Embryo Transfer Cycles

Hassan Ali El-Maghrabi, Yasser Saad El-Kasar, Zeinab Mahmoud Elbaz*, Lamia Youssef

Department of Obstetrics and Gynecology, Faculty of Medicine, Alexandria University, Egypt

*Corresponding author: Zeinab Mahmoud Elbaz, El-shatby Maternity University Hospital, Faculty of Medicine, Alexandria University, Alexandria, Egypt

Received: January 06, 2020; Accepted: January 29, 2020; Published: February 05, 2020

Abstract

Background: Successful implantation requires good embryo quality, appropriately timed and arranged endometrial receptivity, and efficient matching between the embryo and the receptive endometrium.

Objective: The aim of work was to assess the effect of sildenafil citrate on endometrial thickness and pregnancy rate of frozen-thawed embryo transfer cycles.

Subjective: The study was carried out on 40 patients with history of poor endometrial response. Patients were randomly allocated into two equal groups. Group A received estradiol valerat 2mg/tab, three tablets from the first to the 12th day of the menstrual. Group B treated by the same protocol plus sildenafil citrate tablets (50mg) daily from the first day of the cycle until the day of starting progesterone to be stopped 3 days before embryo transfer.

Results: The results of this study showed insignificant difference between the two studied groups regarding endometrial thickness, number of embryo, quality of embryo and pregnancy rate. Conclusion: There was a clinical increase in pregnancy rate in study group more than the control group, but this increasing not significant.

Keywords: Sildenafil Citrate; Endometrial Thickness; Pregnancy Rate; Embryo Transfer Cycles

Introduction

Despite the improvement in ovarian stimulation protocols and subsequent access to a number of dominant follicles, mature oocytes, and embryos for transfer, In Vitro Fertilization (IVF) has successfully reached a plateau. Therefore, more attention should be focused on implantation and endometrial receptivity. Implantation remains a major limiting step of Assisted Reproductive Technology (ART) and uterine receptivity is essential for successful [1] arranged endometrial receptivity, and efficient crosstalk between the embryo and the receptive endometrium. It is thought that the impairment of any one of these factors or [2] during the window. Implantation window is a period during which the endometrium is optimally receptive to implanting blastocyst within the cycle days 20 and 24. It is Endometrial receptivity during the [4,5] implantation in all species. Successful implantation requires good embryo quality, appropriately timed and biological processes may result in implantation failure. The endometrium is normally a non- receptive environment for an embryo, except [3] implantation window depends on the following factors as Endometrial thickness, Endometrial echogenic pattern, Endometrial and sub endometrial blood flows. During implantation window, the endometrial epithelium encompasses four cell types [6]: microvilli-rich cells, pinopode cells, vesiculated cells, and ciliated cells. Treatment options for improving the implantation: (a) blastocyst transfer, (b) assisted hatching, (c) co-culture, (d) preimplantation genetic screening, (e) hysteroscopy, (f) sildenafil citrate, (g) salpingectomy for tubal disease, (h) oocyte donation, (i) transfer of six or more embryos, (j) intratubal embryo transfer, (k) natural-cycle IVF, (l) antiphospholipid antibodies (APA) testing and a vascular connection to the mother.

Estrogen induced endometrial proliferation is in large part dependent upon blood flow treatment, (m) allogenic lymphocyte therapy, and (n) IV immunoglobin therapy [7,8]. Guanyl Monophosphate (cGMP) mediated pathway. Nitric oxide synthase isoforms have been identified in the vascular muscles of both human endometrium and myometrium. Phosphodiesterase (PDE) is a famil of isoenzymes that hydrolyze cyclic nucleotides, such as cGMP. The inhibitors of specific Phosphodiesterase (PDE) subtypes have been identified with an ability to augment the effects of cyclic nucleotides on target tissues as the [8] Phosphodiesterase type 5 (PDE5) that prevents the breakdown of cGMP and potentiates the to the basal endometrium. Nitric Oxide (NO) leads to relaxation of vascular smooth muscles through a cyclic endometrium.

Sildenafil citrate is a potent and selective inhibitor of cGMP specific [9] improvement in uterine blood flow and, in conjunction with estrogen, led to the estrogen- [8] thickening. Endometrium and develop a sustaining blood supply, which requires the following genes to produce the necessary proteins for digesting the endometrial cellular matrix, to regulate cell growth, and to induce angiogenesis: Sildenafil citrate could lead to an Sildenafil citrate enhances uterine blood flow and increases endometrial induced proliferation of the endometrial lining [10].

The achieved implantation depends on the blastocyst’s ability to invade the [7,11,12] Sildenafil citrate was enhanced markedly in p53 and stimulated angiogenic responses [13,14] with increased VEGF. Citrate on ultrasonographic endometrial thickness and pattern and to investigate the estrogen level on the day of progesterone administration, the implantation rate and chemical pregnancy rate in frozen embryo transfer cycles.

The aim of work was to assess the effect of sildenafil citrate on endometrial thickness and pregnancy rate of frozen-thawed embryo transfer cycles.

Methods

A total of 40 patients with history of poor endometrial response to frozen embryo transfer were included in this study. Inclusion criteria were Age less than 40 years. One IVF failure before and High-quality frozen embryos. Exclusion criteria were A history of endocrine diseases like thyroid, DM, Presence of chronic diseases; like cardiovascular, renal and liver diseases and Contraindication to Sildenafil like; hypotension stress, MI.

Patients were randomly allocated into two equal groups. Group A received estradiol valerat 2mg/tab, three tablets from the first to the 12th day of the menstrual. Group B treated by the same protocol plus sildenafil citrate tablets (50mg) daily from the first day of the cycle until the day of starting progesterone to be stopped 3 days before embryo transfer.

Starting on the 11th day of the menstrual cycle, the endometrial thickness was estimated by transvaginal ultrasonography every other day. The evaluations were performed by a single investigator. Once endometrial thickness were more than 8mm, 100mg of progesterone was injected intramuscularly. Endometrial thickness was assessed again on day 3 and day 5 of progesterone treatment. Transfer of frozen embryos occured in day 3of progesterone treatment. Pregnancy test was done to assess pregnancy rate in two groups.

Results

The Age in group I ranged from 22-38 with mean value 29.7±5.038 and in group II ranged from 21-37 with mean value 29.55±5.286. There was no statistical significant difference between two studied groups regarding the age (P> 0.05).

The IVF attempt. IVE attempt in group I was 2.45±0.510 and in group II was 2.35±0.489. There was no statistical significant difference between two studied groups regarding the IVF attempt (P>0.05). Agonist in group I was 13(65%) and in group II was 12(60%) while antagonist was 7(35%) and 8(40%) in both groups respectively. There was no statistical significant difference between two studied groups regarding the protocol used (P>0.05). Endometrial thickness in group I ranged from 7.4-9.5 with mean value 8.875±0.535 and in group II ranged from 7.5-9.4 with mean value 8.85±0.630. There was no statistical significant difference between two studied groups regarding endometrial thickness (P>0.05) (Table 1).

Citation: El-Maghrabi HA, El-Kasar YS, Elbaz ZM, Youssef L. Effect of Sildenafil Citrate on Endometrial Thickness and Pregnancy Rate in Frozen-Thawed Embryo Transfer Cycles. Austin J Obstet Gynecol. 2020; 7(1): 1150.